Unfortunately, the trials of combination therapy of statins with fenofibrate have failed to meet their primary endpoints in terms of reducing cardiovascular events (668,669)
The dual GIP/GLP-1 mechanism appears to be more effective than GLP-1 alone, which is why researchers continue developing multi-receptor agonists
I also met Jesse Kesner founder of Alnu Health, who was featured in Season 2, Episode 4
doi: 10.3389/fphar.2025.1551062 Received 24 December 2024 Accepted 04 April 2025 Published 02 June 2025 Volume 16 - 2025 Edited by Yasmina Mohammed Abd-Elhakim, Zagazig University, Egypt Reviewed by Amany Abdel-Rahman Mohamed, Zagazig University, Egypt Ozlem Demirel, Baheehir University, Trkiye Updates Copyright 2025 Azzam, Anwar, Abd El-Slam, Diab, Ibrahim, Yousef, Sabry, Darwish, Kaliyamoorthy, Salem and Elsanhory